Bonalive is a smart biomaterials company transforming the future of healthcare. With one of the most evidence-based technologies in the industry, we are creating a smarter future for healthcare. Bonalive is an ISO 13485:2016 certified, Class III medical device company.
Mr. Pulkkinen joined Bonalive as CEO on September 1st, 2021. He brings over 20 years of experience from the medical device industry, through former employers including Stryker, Smith and Nephew, and Olympus. Mr. Pulkkinen has been endorsed for his excellent leadership skills and his resolute approach in delivering only the best-quality service and products to customers.
Mrs. Rantala joined Bonalive in 2009 after having held several positions in R&D, quality control and project management. A process-oriented thinker, Rantala believes in a lean working philosophy and mentor-based leadership. She holds a degree in laboratory sciences and is a member of the Finnish Production Management Association.
Mrs Laine joined Bonalive 2020. She has a wide experience from finance, controlling and project management and has held positions for example as a Business Controller and Finance Director. She holds a Bachelor of Business and Administration.
Anne joined the Management team in 2021 shortly after being appointed Bonalive’s new Director Quality. Anne has a master’s degree in biomedicine and has been working in the medical device, pharma and IVD industry for 15 years of which 7 years under the ISO13485 certification and FDA QSR.
Board of Directors
Dr. Ollila has served as Member of the Board of Directors since 2009 and assumed the role of Chairman of the Board in 2018. He founded Bonalive Biomaterials Ltd in 2009 through an MBO of the Bonalive® technology from Vivoxid Ltd, and served as Bonalive’s CEO until August 2021. Before founding Bonalive, Dr. Ollila completed a post-doctoral thesis and worked at Novartis Pharma in Switzerland for several years. He was also the Global Director of Sales and Marketing at Vivoxid Ltd. Ollila holds a doctorate in biochemistry from Åbo Akademi University.
Assoc. Prof. Frantzén has been a Member of the Board of Directors since 2013. As a consultant neurosurgeon and Associate Professor at the Turku University Hospital, Frantzén has extensive experience in the clinical use of bioactive glass in spine surgery. Frantzén holds a PhD in Neurosurgery from the University of Turku.
Mr. Muñoz has been a Member of the Board of Directors since 2017. He has extensive international experience from China, India and Colombia. Currently he serves as a New Business Manager (NBO) and Business Development Director at Avalon Pharmaceuticals.
Mr. Rönnlund was appointed to the Board of Directors in 2019. As a marketing and sales executive in the US and Europe, he has extensive experience from Go-To-Market strategies and brand creation. Mr. Rönnlund holds an MSc in Engineering and an MSc in Economics from Åbo Akademi University.
Mr. Kurokallio was appointed to the Board of Directions in 2020. He has vast experience from working with strategic positions such as the Partner and CEO of Aura Capital, CEO of Stick Tech, Partner of Greenstep and CFO of BCB Medical. Currently he is the General Manager of GC Nordic Ab.
Spine surgery patient casesJuly 2, 2021 11:04
Spine surgery patient cases The first spinal fusion surgery case we want to share with you is of an open posterolateral fusion: Open posterolateral fusion A 44-year-old patient was suffering...
Bonalive in the newsJune 9, 2021 11:18
Helsingin Sanomat | Terveysteknologia: Bonalive featured in the latest health technology issue of the largest newspaper in the Nordics, Helsingin Sanomat. Read the full article
Petteri Pulkkinen to take over as new CEO of Bonalive BiomaterialsJune 7, 2021 09:00
Fredrik Ollila and Petteri Pulkkinen (photo by Jaska Poikonen) Newly recruited by Bonalive Biomaterials, Petteri Pulkkinen brings over 20 years of experience from the medical device industry. His former...
Septic non-union whitepaperMay 20, 2021 11:28
The original whitepaper released in 2017 was developed in collaboration with BG Duisburg (Germany) to give educational advice on how to use bioactive glass in septic non-union surgery. The updated...
Bonalive® granules in ENT product guideMay 11, 2021 13:51
Bonalive® granules is listed in the Otology, Neurotology & Implanted Technology section of the product guide provided by ENT & Audiology News. ENT & Audiology News is an award winning...
Bonalive strengthens its bone infection expertise – Dr. Willemijn Boot joins the teamApril 15, 2021 16:03
We asked Dr. Boot about the latest trends in the field of bone infection treatment and how she sees her new role moving from research to Bonalive Biomaterials. How...
Bone infection patient casesApril 8, 2021 09:20
Septic non-union in the distal tibia A 61-year-old male with an infection of the tibial plate 3 months after Open Reduction Internal Fixation (ORIF) of a closed distal tibia fracture....
Indication of the quarter: Bone infection surgeryApril 1, 2021 12:38
During the second quarter of 2021, Bonalive will highlight solutions for bone infection surgery. Follow us on LinkedIn to stay in the loop, click here. Further material: Bonalive’s Founder...
Bonalive launches the Smart Healing CenterMarch 16, 2021 09:45
To enable surgeon to surgeon interaction, Bonalive is launching a new platform: the Smart Healing Center. The platform is the result of a project financed by Business Finland. We invite...
Mastoidectomy: Why ear surgeons are looking into canal-wall-down as an optionJanuary 19, 2021 16:19
Can you tell us something about mastoidectomy? Various conditions might be treated with mastoidectomy, for instance cholesteatoma where the disease has spread into the mastoid bone. In the mastoidectomy, the...
Mastoid surgery patient casesJanuary 12, 2021 16:31
Obliteration of an old chronically infected mastoid cavity A 57-year old male underwent a radical mastoidectomy in the left ear at the age of 14. The patient suffered from continuous...
Mastoid surgery publication overviewsJanuary 12, 2021 10:32
1. Anatomical, functional and quality-of-life results for mastoid and epitympanic obliteration with bioactive glass s53p4: a prospective clinical study We start off with a publication overview of an article by...
Indication of the quarter: Mastoid surgeryJanuary 8, 2021 13:30
During the first quarter of 2021, Bonalive will highlight solutions for mastoid surgery. To follow us on LinkedIn, click here. Read more about using Bonalive® granules in mastoid surgery...
Smart Healing FoundationDecember 29, 2020 11:58
The Smart Healing Foundation fosters research and innovation projects that contribute to fighting antimicrobial resistance (AMR). With an aim to decrease global use of antibiotics, a special focus is provided...
Preventing antibiotic resistance within surgeryNovember 17, 2020 10:05
Published in Mediuutiset by Ville Kainu, Pfizer and Satu Honkala, Bonalive Biomaterials: The European Antibiotic Awareness Day takes place on November 18. The campaign seeks to raise awareness on antibiotic...
Prevención de la resistencia a los antibióticos en la cirugíaNovember 17, 2020 10:01
Mediuutiset | Ville Kainu, Pfizer, Satu Honkala, Bonalive Biomaterials: La resistencia de las bacterias a los antibióticos ha aumentado a escala mundial, fenómeno que se conoce como resistencia a los...
Verhindern von Antibiotikaresistenzen in der ChirurgieNovember 17, 2020 09:57
Mediuutiset | Ville Kainu, Pfizer, Satu Honkala, Bonalive Biomaterials: Die bakterielle Resistenz gegen Antibiotika hat weltweit zugenommen. Dieses Phänomen ist als Antibiotikaresistenz bekannt. Schätzungen zeigen, dass jährlich etwa 700.000 Menschen...
Prevenzione dell’antibiotico-resistenza in ambito chirurgicoNovember 17, 2020 09:51
Mediuutiset | Ville Kainu, Pfizer, Satu Honkala, Bonalive Biomaterials: A livello globale, la resistenza batterica agli antibiotici è aumentata. Tale fenomeno è noto come resistenza agli antibiotici o antibiotico-resistenza. Si...
Prevenção da resistência aos antibióticos na cirurgiaNovember 17, 2020 09:26
Mediuutiset | Ville Kainu, Pfizer & Satu Honkala, Bonalive Biomaterials: A resistência bacteriana aos antibióticos aumentou a uma escala global. Este fenômeno é conhecido como resistência aos antibióticos. Estimativas indicam...
Highlight of the month OctoberOctober 19, 2020 10:46
By obliterating the mastoid with Bonalive® granules* after Canal Wall Down (CWD) surgery, patients have less cholesteatoma recidivism and less problems associated with their changed middle ear anatomy. Watch the...
Bonalive Biomaterials Ltd
Tel. +358 401 77 44 00
Biolinja 12, 20750 Turku, Finland
ISO 13485:2016 certified
Bonalive® granules, Bonalive® putty and Bonalive® putty MIS are CE marked products.